Log in
Enquire now
POINT Biopharma

POINT Biopharma

POINT Biopharma is a radioligand Therapies founded by Howard Glase.

OverviewStructured DataIssuesContributors

Contents

pointbiopharma.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biotechnology
Biotechnology
Technology
Technology
Biomedical engineering
Biomedical engineering
Healthcare
Healthcare
Engineering
Engineering
Therapeutics
Therapeutics
Biology
Biology
Location
Indianapolis
Indianapolis
0
CEO
‌
Joe McCann
0
Founder
‌
Howard Glase
Pitchbook URL
pitchbook.com/profiles...437830-12
Legal Name
POINT Biopharma Global Inc.0
Number of Employees (Ranges)
51 – 200
Phone Number
+183354426370
Full Address
4850 West 78th St. Indianapolis, Indiana 46268 United States0
Investors
Suvretta Capital
Suvretta Capital
0
Total Funding Amount (USD)
125,000,000
Latest Funding Round Date
September 14, 2022
Stock Symbol
PNT0
Exchange
Nasdaq
Nasdaq
CFO
‌
Bill Demers
0
Latest Funding Type
Initial public offering (IPO)
Initial public offering (IPO)
Patents Assigned (Count)
1
Country
United States
United States
0
Canada
Canada

Other attributes

Company Operating Status
Active
Contact Page URL
pointbiopharma.com/contact-us
Latest Funding Round Amount (USD)
125,000,000
Ticker Symbol
PNT0
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like POINT Biopharma

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.